These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 25001152)

  • 1. Meta-analysis of the influence of chronic kidney disease on the risk of thromboembolism among patients with nonvalvular atrial fibrillation.
    Providência R; Marijon E; Boveda S; Barra S; Narayanan K; Le Heuzey JY; Gersh BJ; Gonçalves L
    Am J Cardiol; 2014 Aug; 114(4):646-53. PubMed ID: 25001152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies.
    Dahal K; Kunwar S; Rijal J; Schulman P; Lee J
    Chest; 2016 Apr; 149(4):951-9. PubMed ID: 26378611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stroke and bleeding in atrial fibrillation with chronic kidney disease.
    Olesen JB; Lip GY; Kamper AL; Hommel K; Køber L; Lane DA; Lindhardsen J; Gislason GH; Torp-Pedersen C
    N Engl J Med; 2012 Aug; 367(7):625-35. PubMed ID: 22894575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety.
    Salim I; Al Suwaidi J; Ghadban W; Salam AM
    Expert Opin Drug Saf; 2013 Jan; 12(1):53-63. PubMed ID: 23095103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Continuation of statin therapy and a decreased risk of atrial fibrillation/flutter in patients with and without chronic kidney disease.
    Chang CH; Lee YC; Tsai CT; Chang SN; Chung YH; Lin MS; Lin JW; Lai MS
    Atherosclerosis; 2014 Jan; 232(1):224-30. PubMed ID: 24401243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.
    Eikelboom JW; Connolly SJ; Gao P; Paolasso E; De Caterina R; Husted S; O'Donnell M; Yusuf S; Hart RG
    J Stroke Cerebrovasc Dis; 2012 Aug; 21(6):429-35. PubMed ID: 22818021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of thromboembolic events in atrial fibrillation with chronic kidney disease.
    Zeng WT; Sun XT; Tang K; Mei WY; Liu LJ; Xu Q; Cheng YJ
    Stroke; 2015 Jan; 46(1):157-63. PubMed ID: 25424480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Haemorragic and thromboembolic risk in CKD patients with non valvular atrial fibrillation: Do we need a novel risk score calculator?
    Ravera M; Bussalino E; Paoletti E; Bellasi A; Di Lullo L; Fusaro M
    Int J Cardiol; 2019 Jan; 274():179-185. PubMed ID: 30177235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk.
    Bhatia HS; Hsu JC; Kim RJ
    Clin Cardiol; 2018 Oct; 41(10):1395-1402. PubMed ID: 30259531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic Kidney Disease, Time in Therapeutic Range and Adverse Clinical Outcomes in Anticoagulated Patients with Non-valvular Atrial Fibrillation: Observations from the SPORTIF Trials.
    Proietti M; Lane DA; Lip GYH
    EBioMedicine; 2016 Jun; 8():309-316. PubMed ID: 27428440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stroke prevention in atrial fibrillation patients with chronic kidney disease.
    Hart RG; Eikelboom JW; Brimble KS; McMurtry MS; Ingram AJ
    Can J Cardiol; 2013 Jul; 29(7 Suppl):S71-8. PubMed ID: 23790601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis.
    Ruiz-Nodar JM; Marín F; Hurtado JA; Valencia J; Pinar E; Pineda J; Gimeno JR; Sogorb F; Valdés M; Lip GY
    J Am Coll Cardiol; 2008 Feb; 51(8):818-25. PubMed ID: 18294566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Periprocedural stroke and bleeding complications in patients undergoing catheter ablation of atrial fibrillation with different anticoagulation management: results from the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) randomized trial.
    Di Biase L; Burkhardt JD; Santangeli P; Mohanty P; Sanchez JE; Horton R; Gallinghouse GJ; Themistoclakis S; Rossillo A; Lakkireddy D; Reddy M; Hao S; Hongo R; Beheiry S; Zagrodzky J; Rong B; Mohanty S; Elayi CS; Forleo G; Pelargonio G; Narducci ML; Dello Russo A; Casella M; Fassini G; Tondo C; Schweikert RA; Natale A
    Circulation; 2014 Jun; 129(25):2638-44. PubMed ID: 24744272
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preoperative atrial fibrillation increases risk of thromboembolic events after left ventricular assist device implantation.
    Stulak JM; Deo S; Schirger J; Aaronson KD; Park SJ; Joyce LD; Daly RC; Pagani FD
    Ann Thorac Surg; 2013 Dec; 96(6):2161-7. PubMed ID: 24035302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain and kidney, victims of atrial microembolism in elderly hospitalized patients? Data from the REPOSI study.
    Corrao S; Argano C; Nobili A; Marcucci M; Djade CD; Tettamanti M; Pasina L; Franchi C; Marengoni A; Salerno F; Violi F; Mannucci PM; Perticone F;
    Eur J Intern Med; 2015 May; 26(4):243-9. PubMed ID: 25749554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment patterns and real-world effectiveness of warfarin in nonvalvular atrial fibrillation within a managed care system.
    Darkow T; Vanderplas AM; Lew KH; Kim J; Hauch O
    Curr Med Res Opin; 2005 Oct; 21(10):1583-94. PubMed ID: 16238898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
    Ahmad Y; Lip GY
    Contrib Nephrol; 2013; 179():81-91. PubMed ID: 23652451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thromboembolism and bleeding in patients with atrial fibrillation and stage 4 chronic kidney disease: impact of biomarkers.
    Matusik PT; Leśniak WJ; Heleniak Z; Undas A
    Kardiol Pol; 2021; 79(10):1086-1092. PubMed ID: 34392517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower-dose warfarin delays renal progression and prolongs patient survival in patients with stage 3 - 5 chronic kidney disease and nonvalvular atrial fibrillation: a 12-year follow-up study.
    Chiu PF; Huang CH; Liou HH; Wu CL; Chang C; Chang CC; Chang HR
    Int J Clin Pharmacol Ther; 2014 Jun; 52(6):504-8. PubMed ID: 24755133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.